Novartis caught in the Stormy Daniels affair, after huge payment to Trump’s lawyer

pharmafile | May 9, 2018 | News story | Medical Communications, Research and Development Cohen, Novartis, President trump, Trump, biotech, drugs, pharma, pharmaceutical 

Novartis has suddenly found itself embroiled in the Stormy Daniels affair, after the lawyer representing her, Michael Avenatti, included the Basel-based pharma company in a series of payments made to a company set up by President Trump’s personal lawyer, Michael Cohen.

Avenatti revealed that Novartis had made four payments of $99,980, with the payments ending in January – not long before CEO Vas Narasimhan met with Trump in February.

The money was ended up in the bank account of Essential Consultants, a company that Cohen set up shortly before the presidential election. It was an account from the same company that transferred $130,000 to a representative of Daniels to allegedly buy her silence regarding an affair she may have had with Trump.

Having such a direct link to a hugely controversial case is not ideal for Novartis, as it is also at the centre of an equally damaging bribery case in Greece that has implicated a number of government officials.

In a statement, a Novartis spokesman said, “Any agreements with Essential Consultants were entered before our current CEO taking office in February of this year and have expired.”

Novartis was not the only company allegedly involved in making such payments to Cohen’s company; Avenatti also revealed that $500,000 had been paid into the same account by Columbus Nova – a company that has affiliations to Russian oligarch, Viktor Vekselberg.

In addition, AT&T also paid $200,000 in four payments to Essential Consultants, leading up to an attempted merger with Time Warner, which was initially blocked by the Department of Justice. While the other payment, revealed Avenatti, was made by Korea Aerospace Industries as a single payment of $150,000.

The revelations highlight the murky affairs that play out in the background of political lobbying but, unusually, have now been brought to light by a shared link to the Trump-Daniels affair that has occupied headlines for the last few weeks.

Ben Hargreaves

Related Content

AstraZeneca and MSD’s Lynparza receives NICE positive recommendation as a cancer maintenance treatment

UK-based pharmaceutical company AstraZeneca has announced that the National Institute for Health and Care Excellence …


Astellas Pharma and BMT CTN announce phase 3 data for gilteritinib

Japanese pharmaceutical company Astellas Pharma and the Blood and Marrow Transplant Clinical Trials Network (BMT …

Novartis Cosentyx® gains positive CHMP opinion for hidradenitis suppurativa

Basel, April 26, 2023 — Novartis announced today that the Committee for Medicinal Products for Human …

Latest content